Rheumatoid arthritis: Pathological mechanisms and modern pharmacologic therapies

Qiang Guo, Yuxiang Wang, Dan Xu, Johannes Nossent, Nathan J. Pavlos, Jiake Xu

Research output: Contribution to journalReview article

33 Citations (Scopus)

Abstract

Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease that primarily affects the lining of the synovial joints and is associated with progressive disability, premature death, and socioeconomic burdens. A better understanding of how the pathological mechanisms drive the deterioration of RA progress in individuals is urgently required in order to develop therapies that will effectively treat patients at each stage of the disease progress. Here we dissect the etiology and pathology at specific stages: (i) triggering, (ii) maturation, (iii) targeting, and (iv) fulminant stage, concomitant with hyperplastic synovium, cartilage damage, bone erosion, and systemic consequences. Modern pharmacologic therapies (including conventional, biological, and novel potential small molecule disease-modifying anti-rheumatic drugs) remain the mainstay of RA treatment and there has been significant progress toward achieving disease remission without joint deformity. Despite this, a significant proportion of RA patients do not effectively respond to the current therapies and thus new drugs are urgently required. This review discusses recent advances of our understanding of RA pathogenesis, disease modifying drugs, and provides perspectives on next generation therapeutics for RA.

Original languageEnglish
Article number16
JournalBone Research
Volume6
Issue number1
DOIs
Publication statusPublished - 1 Dec 2018

Fingerprint

Rheumatoid Arthritis
Therapeutics
Joints
Antirheumatic Agents
Premature Mortality
Synovial Membrane
Pharmaceutical Preparations
Autoimmune Diseases
Cartilage
Pathology
Bone and Bones

Cite this

@article{f30e319ef5324da0950834c3d89a64dd,
title = "Rheumatoid arthritis: Pathological mechanisms and modern pharmacologic therapies",
abstract = "Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease that primarily affects the lining of the synovial joints and is associated with progressive disability, premature death, and socioeconomic burdens. A better understanding of how the pathological mechanisms drive the deterioration of RA progress in individuals is urgently required in order to develop therapies that will effectively treat patients at each stage of the disease progress. Here we dissect the etiology and pathology at specific stages: (i) triggering, (ii) maturation, (iii) targeting, and (iv) fulminant stage, concomitant with hyperplastic synovium, cartilage damage, bone erosion, and systemic consequences. Modern pharmacologic therapies (including conventional, biological, and novel potential small molecule disease-modifying anti-rheumatic drugs) remain the mainstay of RA treatment and there has been significant progress toward achieving disease remission without joint deformity. Despite this, a significant proportion of RA patients do not effectively respond to the current therapies and thus new drugs are urgently required. This review discusses recent advances of our understanding of RA pathogenesis, disease modifying drugs, and provides perspectives on next generation therapeutics for RA.",
author = "Qiang Guo and Yuxiang Wang and Dan Xu and Johannes Nossent and Pavlos, {Nathan J.} and Jiake Xu",
year = "2018",
month = "12",
day = "1",
doi = "10.1038/s41413-018-0016-9",
language = "English",
volume = "6",
journal = "Bone Research",
issn = "2095-4166",
publisher = "Nature Publishing Group - Macmillan Publishers",
number = "1",

}

Rheumatoid arthritis : Pathological mechanisms and modern pharmacologic therapies. / Guo, Qiang; Wang, Yuxiang; Xu, Dan; Nossent, Johannes; Pavlos, Nathan J.; Xu, Jiake.

In: Bone Research, Vol. 6, No. 1, 16, 01.12.2018.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Rheumatoid arthritis

T2 - Pathological mechanisms and modern pharmacologic therapies

AU - Guo, Qiang

AU - Wang, Yuxiang

AU - Xu, Dan

AU - Nossent, Johannes

AU - Pavlos, Nathan J.

AU - Xu, Jiake

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease that primarily affects the lining of the synovial joints and is associated with progressive disability, premature death, and socioeconomic burdens. A better understanding of how the pathological mechanisms drive the deterioration of RA progress in individuals is urgently required in order to develop therapies that will effectively treat patients at each stage of the disease progress. Here we dissect the etiology and pathology at specific stages: (i) triggering, (ii) maturation, (iii) targeting, and (iv) fulminant stage, concomitant with hyperplastic synovium, cartilage damage, bone erosion, and systemic consequences. Modern pharmacologic therapies (including conventional, biological, and novel potential small molecule disease-modifying anti-rheumatic drugs) remain the mainstay of RA treatment and there has been significant progress toward achieving disease remission without joint deformity. Despite this, a significant proportion of RA patients do not effectively respond to the current therapies and thus new drugs are urgently required. This review discusses recent advances of our understanding of RA pathogenesis, disease modifying drugs, and provides perspectives on next generation therapeutics for RA.

AB - Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease that primarily affects the lining of the synovial joints and is associated with progressive disability, premature death, and socioeconomic burdens. A better understanding of how the pathological mechanisms drive the deterioration of RA progress in individuals is urgently required in order to develop therapies that will effectively treat patients at each stage of the disease progress. Here we dissect the etiology and pathology at specific stages: (i) triggering, (ii) maturation, (iii) targeting, and (iv) fulminant stage, concomitant with hyperplastic synovium, cartilage damage, bone erosion, and systemic consequences. Modern pharmacologic therapies (including conventional, biological, and novel potential small molecule disease-modifying anti-rheumatic drugs) remain the mainstay of RA treatment and there has been significant progress toward achieving disease remission without joint deformity. Despite this, a significant proportion of RA patients do not effectively respond to the current therapies and thus new drugs are urgently required. This review discusses recent advances of our understanding of RA pathogenesis, disease modifying drugs, and provides perspectives on next generation therapeutics for RA.

UR - http://www.scopus.com/inward/record.url?scp=85045963526&partnerID=8YFLogxK

U2 - 10.1038/s41413-018-0016-9

DO - 10.1038/s41413-018-0016-9

M3 - Review article

VL - 6

JO - Bone Research

JF - Bone Research

SN - 2095-4166

IS - 1

M1 - 16

ER -